A team of scientists at Penn Medicine’s Abramson Cancer Center looked at why tumors with more T cells, or cells that play a vital role in the immune response, are more sensitive to immunotherapy than those with fewer T cells. Those with more of these cells are known as “hot” tumors and those with less are known as “cold.” Read more . . .
A new study published this week in Immunity could change the way oncologists tailor treatments to a patient’s specific type of tumor.